GS-7977 with interferon/ribavirin cures most treatment-naive hepatitis C patients in 12 weeks
![Kris Kowdley, Virginia Mason Medical Center, Seattle [Photo by Liz Highleyman, hivandhepatitis.com]](https://ik.imagekit.io/ftwmbwg7i/tr:w-640,h-480,q-80,fo-auto,f-auto/https%3A%2F%2Fcdn.craft.cloud%2F019ecfe4-fa59-7378-875f-6ad629d65a81%2Fassets%2F2012-04%2Fgs-7977-with-interferon-ribavirin-cures-most-treatment-naive-hepatitis-c-patients-in-12-weeks.jpg?ik-s=162dce97971b5a079c73f39b4d72ea056f715705&ik-t=7552444800)
Abbott interferon-free HCV combinations show early promise in untreated patients
Boceprevir a useful option for patients who did not respond to earlier course of hepatitis C therapy
Adding TMC435 boosts response for difficult-to-treat hepatitis C patients
Hepatitis C drug alisporivir is effective, but pancreatitis a concern
Telaprevir and boceprevir show high rate of serious side-effects in hepatitis C patients with urgent need of treatment
Hepatitis C meds GS-7977, daclatasvir and asunaprevir look good in interferon-free combos
